| Budget Amount *help |
¥217,880,000 (Direct Cost: ¥167,600,000、Indirect Cost: ¥50,280,000)
Fiscal Year 2016: ¥46,020,000 (Direct Cost: ¥35,400,000、Indirect Cost: ¥10,620,000)
Fiscal Year 2015: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2014: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2013: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2012: ¥27,560,000 (Direct Cost: ¥21,200,000、Indirect Cost: ¥6,360,000)
|
|---|
| Outline of Final Research Achievements |
By metabolomics-based studies, we obtained the following findings: (1) discovery that glutamate acts as a key signal in potentiation of insulin secretion by the gut hormone called "incretin"; (2) difference in metabolic profiling between pancreatic exocrine-derived iPS cells and fibroblast-derived iPS cells; and (3) identification of plasma tryptophan as a candidate biomarker for early diagnosis of type 2 diabetes. In addition, we found that Epac2A in pancreatic beta-cells is critical for the augmenting effect of insulin secretion by combination of anti-diabetic sulfonylurea drug and incretin. We also identified a small molecule diphenylthiosemicarbazide that potentially leads to the development of a novel anti-diabetic drug.
|
